Cryosite Limited (AU:CTE)
ASX:CTE
Want to see AU:CTE full AI Analyst Report?
CTE Stock Chart & Stats
AU$1.00
-AU$0.05(-6.02%)
At close: 4:00 PM EST
AU$1.00
-AU$0.05(-6.02%)
Day’s Range― - ―
52-Week RangeAU$0.60 - AU$1.30
Previous CloseN/A
Volume1.46K
Average Volume (3M)1.97K
Market Cap
AU$51.74M
Enterprise ValueAU$59.97M
Total Cash (Recent Filing)AU$2.54M
Total Debt (Recent Filing)AU$8.82M
Price to Earnings (P/E)23.7
Beta-0.20
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding48,809,563
10 Day Avg. Volume3,337
30 Day Avg. Volume1,969
Financial Highlights & Ratios
PEG Ratio8.08
Price to Book (P/B)15.22
Price to Sales (P/S)2.58
P/FCF Ratio24.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthA 9.85% reported revenue increase indicates durable demand and expanding market penetration in diagnostics/research. Sustained top-line growth supports reinvestment in products and distribution, enabling scale benefits and reducing unit costs over the next several quarters.
High Profitability And MarginsVery strong gross margins (62.98%) and healthy net margin (13.35%) reflect pricing power and an efficient cost base. These margin levels provide durable earnings resilience, fund operating needs and R&D, and create a buffer against moderate revenue volatility over the medium term.
Very High Return On EquityROE of 78.86% signals exceptional efficiency in converting equity into profit, implying strong capital allocation or a compact equity base producing high returns. Over time this can enhance shareholder value if sustained and supports reinvestment without heavy equity issuance.
Bears Say
Declining Free Cash Flow GrowthA 32.88% drop in free cash flow growth and operating cash flow below net income indicate weaker cash conversion. Persistent FCF declines constrain internal funding for capex, R&D, or expansion, increasing reliance on external financing and raising medium-term execution risk.
Material Leverage And Low Equity RatioDebt-to-equity near 0.95 and a low equity ratio show meaningful dependence on debt financing. Elevated leverage reduces financial flexibility, raises interest burden sensitivity, and heightens risk if revenue or cash flows weaken, limiting strategic optionality over the next several quarters.
Emerging Cost Pressure On Gross MarginA slight year-over-year decline in gross margin points to rising input costs or pricing pressure. If this trend persists, it could erode the company’s high-margin profile and require margin-restoring actions (cost cuts or price increases) that may impair growth or competitive position.
Cryosite Limited News
CTE FAQ
What was Cryosite Limited’s price range in the past 12 months?
Cryosite Limited lowest share price was AU$0.60 and its highest was AU$1.30 in the past 12 months.
What is Cryosite Limited’s market cap?
Cryosite Limited’s market cap is AU$51.74M.
When is Cryosite Limited’s upcoming earnings report date?
Cryosite Limited’s upcoming earnings report date is Aug 21, 2026 which is in 77 days.
How were Cryosite Limited’s earnings last quarter?
Cryosite Limited released its earnings results on Feb 26, 2026. The company reported AU$0.023 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.023.
Is Cryosite Limited overvalued?
According to Wall Street analysts Cryosite Limited’s price is currently Overvalued.
Does Cryosite Limited pay dividends?
Cryosite Limited pays a Annually dividend of AU$0.02 which represents an annual dividend yield of N/A. See more information on Cryosite Limited dividends here
What is Cryosite Limited’s EPS estimate?
Cryosite Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cryosite Limited have?
Cryosite Limited has 48,809,563 shares outstanding.
What happened to Cryosite Limited’s price movement after its last earnings report?
Cryosite Limited reported an EPS of AU$0.023 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cryosite Limited?
Currently, no hedge funds are holding shares in AU:CTE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cryosite Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.34%
12-Months-Change
Fundamentals
Return on Equity
72.82%
Trailing 12-Months
Asset Growth
39.09%
Trailing 12-Months
Company Description
Cryosite Limited
Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns management, comparator sourcing, import, export, validated transport, and biological storage solutions to the clinical trials, and research and pharmaceutical industry. The Cord Blood and Tissues Storage segment offers long term storage solutions for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. The company was incorporated in 1999 and is based in South Granville, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Inoviq Ltd
―
Microba Life Sciences Limited
―
Options Prices
Currently, No data available
---